


<div>  </div>		<div> AETNA BETTER HEALTH® Coverage Policy/Guideline </div>	
Name:	Zurzuvae (zuranolone)	Page:	1 of 1
Effective Date:	5/30/2025	Last Review Date:	5/12/2025
Applies to:	<input checked="" type="checkbox"/> Illinois		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Zurzuvae under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Zurzuvae is indicated for the treatment of postpartum depression (PPD) in adults.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Zurzuvae

Policy/Guideline:

Criteria for Approval

Post-partum depression (PPD)

Authorization may be granted for treatment of post-partum depression in adults when the following criteria are met:

- A. Member is 12 months postpartum or less.
- B. Member will not receive more than one 14-day treatment course per pregnancy / childbirth.

Approval Duration and Quantity Restrictions:

Approval Duration: One Month

Quantity Level Limit: 28 capsules per 14 days

References:

1. Zurzuvae [package insert]. Cambridge, MA: Sage Therapeutics, Inc.; July 2024.